Consistent with FDA labeling, GLP-1 RAs amplify hypoglycemia risk when combined with insulin or sulfonylureas 42 , a complication linked to seizures, syncope, and tremors 43
It could effectively reduce the levels of key pro-inflammatory factors such as TNF-, IL-6, and high mobility group box protein 1, thereby effectively alleviating the inflammatory response in muscle tissue [27]
Clinical Pearls How do corticosteroids promote weight gain
Bigio B, Math AA, Sousa VC, Zelli D, Svenningsson P, McEwen BS, Nasca C
VivioMD's compounded tirzepatide injection is likewise prepared by an independent compounding pharmacy and has not undergone FDA review as a finished product
Neuroimage 54 , 28082821